Cipla Moves Into mRNA Arena With Stake In German Biotech Ethris

Jan 03 2023

• By Anju Ghangurde

Listen to this article

Cipla set to hold 10.35% in biotech Ethris, which is progressing inhaled mRNA-based therapies, among other key assets. The Indian firm expects its next wave of growth to come from areas like biosimilars and mRNA alongside lung leadership aspirations, putting the spotlight on the broader direction of the deal.

Cipla-Ethris ally to develop mRNA-based therapies • Source: Shutterstock

Cipla Limited’s efforts to shepherd Moderna, Inc.’s messenger RNA (mRNA) COVID-19 vaccine to India may not have gone as per plan in 2021, but the Indian company isn’t going to sit on the sidelines anymore and watch the action build around the promising new star modality.(Also see "More Indian Firms Dip Toes In Vaccines Segment: Just 'Opportunistic'?" - Scrip, 3 January, 2022.)(Also see "Tracing Cipla’s Interest In Vaccines, Potential For Tie-Up With Moderna" - Scrip, 28 May, 2021.)

The Mumbai-based firm has, via its wholly owned UK subsidiary, Cipla (EU) Limited, entered into definitive agreements to acquire about...

More from Business

Test Roche Head Of Pharma Strategy Karsten Jung On Rebuilding The Portfolio
Jan 23 2026
• By Jessica Merrill
The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.
Quick Listen: Scrip’s Five Must-Know Things
Dec 09 2025
• By Reed Miller
In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.
Article Without An Author Listed
Nov 19 2025
Here is a short description.
Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]
Nov 12 2025
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance
Jul 15 2026
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone
Jun 18 2026
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Finance Watch: Biopharma IPOs On The Upswing, Including Ex-US Offerings
Jun 17 2026
ghghghghghjhjhjhj